language_icon
EN
HI

Novelix Pharmaceuticals Share price

NOVELIX

55.5

0.47 (0.85%)
Last updated on 24 Apr, 2026 | 15:29 IST
Today's High

55.90

Today's Low

54.00

52 Week Low

26.61

52 Week High

70.16

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Novelix Pharmaceuticals Chart

Novelix Pharmaceuticals Share Key Metrics

Volume
2267.00
Market Cap
96.94 CR
LTQ@LTP
80@55.50
ATP
55.02
Var Margin
25 %
Circuit Range
44.03-66.03
Delivery %
93.25 %
Value
1.25 L
ASM/GSM
No
Market Lot
1

Summary

24 Apr, 2026 | 15:29 को, Novelix Pharmaceuticals का शेयर प्राइस आज ₹55.5 पर है, जो दिन के लिए 0.47% की 0.85 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹54.00 और ₹55.90 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹26.61 से ₹70.16 तक रही है। ट्रेडिंग गतिविधि के मामले में, Novelix Pharmaceuticals ने 2267 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹17615000 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹5502 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 80,5550 रही। यह स्टॉक ₹44.03-66.03 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹1.25 L है। दिन के लिए डिलीवरी परसेंटेज 93.25% रही। इसके अतिरिक्त, Novelix Pharmaceuticals वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Novelix Pharmaceuticals Fundamentals

View More
P/E Ratio

0

P/B Ratio

0

Div. Yield

0

Sector P/E

42.8

Sector P/B

2.07

Sec. Div. Yield

80.53

Novelix Pharmaceuticals Resistance and Support

Pivot 55.67

Resistance

First Resistance

57.34

Second Resistance

59.66

Third Resistance

61.33

Support

First Support

53.35

Second Support

51.68

Third Support

49.36

Novelix Pharmaceuticals Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

66.56%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0%

Domestic Institutional Investors

0%

Retail

33.44%

Others

0%

Total Promoters
MAR '24
66.92%
JUN '24
66.54%
SEP '24
66.56%
DEC '24
66.56%

Novelix Pharmaceuticals Corporate Actions

DateAgenda
2026-02-12Quarterly Results

Novelix Pharmaceuticals News

Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Novelix Pharmaceuticals promoters Srinidhi Fine-Chemicals LLP and Narahari Belide acquired 1.15 million shares. This acquisition on March 30, 2026, was through conversion of warrants via a preferential allotment, increasing their combined stake in the company.
Apr 02 2026 10:04:00

Novelix Pharmaceuticals Ltd - 536565 - Announcement under Regulation 30 (LODR)-Allotment

Novelix Pharmaceuticals allotted 11.5 lakh equity shares from warrant conversion at ₹20 each. This capital raise generated ₹2.3 crore and increased the company's paid-up equity capital to ₹2.10 crore.
Mar 31 2026 15:03:00

Novelix Pharmaceuticals Ltd - 536565 - Intimation Under Regulation 30 (LODR), Regulations 2015- Reconstitution Of Committees.

Novelix Pharmaceuticals board reconstituted its Audit, Nomination & Remuneration, and Stakeholders Relationship Committees. Janardhan Das Kabra will chair the Audit and N&R Committees, while Sridevi Belide will lead the Stakeholders Relationship Committee, effective March 30, 2026.
Mar 31 2026 15:03:00

Novelix Pharmaceuticals Ltd - 536565 - Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th April, 2026

Novelix Pharmaceuticals board approved the allotment of 11.5 lakh equity shares at ₹20 each upon warrant conversion. This increased the paid-up equity capital to ₹2.1085 crore. Additionally, the board accepted the resignation of Non-Executive Director Jivamohan Divakar Valluri, effective March 30, 2026.
Mar 30 2026 19:03:00
Read More

About Novelix Pharmaceuticals AboutThe

NSE : 0  
BSE : 536565  
ISIN : INE314I01036  

The Company was incorporated on 13.12.94 as a Public Ltd companyunder the Companies Act 1956 under the name and style of"Trimurthi Securities Limited". It obtained the Certificate ofCommencement of Business on 19.12.94 with a view to carry on thebusiness of investment in Securities Leasing of all types ofMotor Vehicles Consumer Durables and Equipment ProjectConsultancy and for accepting Fixed Deposits and InterCorporate Deposits. The Registered Office of the Company waschanged to 303 3rd Floor Doshi Chambers 36-327 & 328Basheerbagh Hyderabad - 500029 vide Resolution of the Board ofDirectors dated 10.02.95.The Company is promoted by Mr. Gopi Kishan Bhangadia and Mr.ArunKumar Bhangadia.MAIN OBJECTS OF THE COMPANYThe main objects of the company as set out in its Memorandum ofAssociation are as follows :1. To carry on the business of stock broker sub-broker dealerjobber market maker portfolio manager underwriter dealersor broker or agent in securities financial instruments capitalmarkets money market instruments of all kinds Company depositsnational savings certificates and other government securitiesissued or guaranteed by a body corporate Company public sectorCompany government municipality or any body in India orabroad whether they are listed or not for the time being andto acquire or takeover the business of any individualpartnership or corporate body carrying on business/professionas brokers sub-brokers underwriters jobbers members agentstraders of all types of shares and stocks. To hold one or moremembership of any recognised stock exchange of India/OTCexchange of India/ National Stock Exchange of India.2. To acquire hold sell buy or otherwise deal in any sharesunits stocks debentures debenture-stock bonds mortgagesobligations and other securities by original subscriptiontender purchase change gift or otherwise and to subscribe forthe same either conditionally or otherwise and to underwritesub-underwrite or guarantee the subscription thereof to purchaseand sell above mentioned securities.3. To establish and carry on the business of merchant bankingand to provide custodian and depository services to act asclearing house portfolio manager registrars share transferagents lead managers co-managers managers of investmentpools advisors and consultants to raise capital either throughpublic issue or otherwise and to provide the services oracquire securities in connection with the amalgamationstakeovers and reconstructions of Companies and to arrange orparticipate in bought out deals and placements of shares andother securities.OTHER OBJECTS10. To carry on the business of finance hire-purchase leasingand investments.At the Extra Ordinary General Meeting of the Company held on29.12.1994 the Members passed a Spedal Resolution and accordedapproval to the Company to commence the business of LeasingHire Purchase Finance and Investment as specified in Subclause10 of Objects clause C of the Memorandum of Association of theCompany.

Read More

Novelix Pharmaceuticals Management

NamePosition
Venkateshwarlu PulluruWhole Time Director
Janardhan Das KabraNon Executive Independent Director
View More

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals शेयर का खरीद मूल्य 55.5 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Novelix Pharmaceuticals शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Novelix Pharmaceuticals शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 0 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Novelix Pharmaceuticals शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 0 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Novelix Pharmaceuticals शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.07 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Novelix Pharmaceuticals का मार्केट कैप 96.94 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Novelix Pharmaceuticals शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 70.16 और 26.61 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost